Highlights of recent developments and trends in cancer nanotechnology research--view from NCI Alliance for Nanotechnology in Cancer.
Although the incidence of cancer and cancer related deaths in the United States has decreased over the past two decades due to improvements in early detection and treatment, cancer still is responsible for a quarter of the deaths in this country. There is much room for improvement on the standard treatments currently available and the National Cancer Institute (NCI) has recognized the potential for nanotechnology and nanomaterials in this area. The NCI Alliance for Nanotechnology in Cancer was formed in 2004 to support multidisciplinary researchers in the application of nanotechnology to cancer diagnosis and treatment. The researchers in the Alliance have been productive in generating innovative solutions to some of the central issues of cancer treatment including how to detect tumors earlier, how to target cancer cells specifically, and how to improve the therapeutic index of existing chemotherapies and radiotherapy treatments. Highly creative ideas are being pursued where novelty in nanomaterial development enables new modalities of detection or therapy. This review highlights some of the innovative materials approaches being pursued by researchers funded by the NCI Alliance. Their discoveries to improve the functionality of nanoparticles for medical applications includes the generation of new platforms, improvements in the manufacturing of nanoparticles and determining the underlying reasons for the movement of nanoparticles in the blood.
Office of Cancer nanotechnology Research, Center for Strategic Initiatives, National Cancer Institute, NIH, 31 Center Drive, Bethesda, MD 20892, USA. Electronic address: lynn.hull@nih.gov.
L C
LC
Hull
Office of Cancer nanotechnology Research, Center for Strategic Initiatives, National Cancer Institute, NIH, 31 Center Drive, Bethesda, MD 20892, USA. Electronic address: dorothy.farrell@nih.gov.
D
D
Farrell
Office of Cancer nanotechnology Research, Center for Strategic Initiatives, National Cancer Institute, NIH, 31 Center Drive, Bethesda, MD 20892, USA. Electronic address: piotr.grodzinski@nih.gov.
P
P
Grodzinski
D000818:Animals; D015415:Biomarkers; D004358:Drug Therapy / Q000379:methods; D006046:Gold / Q000737:chemistry; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D053768:Metal Nanoparticles / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry; D036103:Nanotechnology / Q000379:methods*; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000628:therapy*; D009690:Nucleic Acid Conformation; D012313:RNA / Q000737:chemistry; D011878:Radiotherapy / Q000379:methods; D014481:United States
D015415:Biomarkers; D008081:Liposomes; D012313:RNA; D006046:Gold
Alliance; Cancer; Nanotechnology